BioRegenx is a small, early-stage health and wellness company operating through four subsidiaries. The company was formed through a reverse merger in March 2024, when a private health-focused entity merged into Findit, a shell company. The core revenue-generating business runs through two subsidiaries: MVHS and NuLife Sciences. MVHS produces and sells Endocalyx Pro, a patented dietary supplement targeting microvascular (capillary) health, and GlycoCheck, a patented Class I medical device that non-invasively measures microvascular health. GlycoCheck is sold to academic research hospitals, medical practices, and wellness practitioners at $14,900–$32,000 per system, with recurring per-scan fees creating a razor-and-blades revenue dynamic. NuLife Sciences markets and distributes these products alongside a broader line of wellness devices through practitioners, affiliates, and online channels including Amazon and Walmart. A third subsidiary, DocSun BioMedical, is developing an AI engine that uses facial scanning to measure vital signs; DocSun has signed distribution and licensing agreements but has not yet generated revenue, and its TruScan.AI mobile app is not expected to launch until Q3 2027. The fourth subsidiary, Findit AI Connect, operates a legacy social media and search platform that BioRegenx intends to use primarily as an internal marketing tool. BioRegenx generates roughly 93% of its revenue from U.S. customers and employs only 6 full-time employees. The company remains pre-profitability on most of its newer initiatives.